Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 3/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
| ▸ | TNKS | O95271 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13155401 | 0.77 | L3MBTL1 (0.42) | NUDT1L3MBTL1TNKSKMT2A | |
| SCHEMBL15066160 | 0.77 | NUDT1 (0.31) | NUDT1 | |
| SCHEMBL104884 | 0.75 | HTR2C (0.47) | NUDT1L3MBTL1TNKS | |
| SCHEMBL10282182 | 0.75 | NUDT1 (0.41) | NUDT1L3MBTL1TNKS | |
| SCHEMBL13693180 | 0.75 | L3MBTL1 (0.38) | NUDT1L3MBTL1TNKS | |
| SCHEMBL8240995 | 0.72 | L3MBTL1 (0.35) | NUDT1L3MBTL1 | |
| SCHEMBL104697 | 0.72 | L3MBTL1 (0.35) | NUDT1L3MBTL1HCRTR2KMT2A | |
| SCHEMBL22641191 | 0.71 | NUDT1 (0.41) | NUDT1L3MBTL1KMT2A | |
| SCHEMBL10250872 | 0.71 | PDE10A (0.34) | HTR6 | |
| SCHEMBL14507510 | 0.70 | PTGS1 (0.40) | L3MBTL1HTR6TNKS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2460805-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | Oncotherapy Science, Inc. (JP) | 2012-06-06 | — | — | EP | disclosed |
| EP-2460805-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | Oncotherapy Science, Inc. (JP) | 2012-06-06 | — | — | EP | disclosed |
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
| WO-2011013729-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | オンコセラピー・サイエンス株式会社 (JP) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | NR0B1, GRK7, NR5A2 | NUDT1 3935/4885L3MBTL1 4139/4885HTR6 2727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.